By creator to www.biospace.com
SOUTH SAN FRANCISCO, Calif., Might 05, 2020 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a number one precision medication firm centered on the invention, improvement, and commercialization of clinically differentiated, high-value healthcare options for transplant sufferers and caregivers, at this time introduced a strategic alliance with Weill Cornell Medicine that makes CareDx the unique improvement and commercialization companion of UroMap, a urine-based gene-expression take a look at for acute mobile rejection in kidney transplant recipients.
CareDx is collaborating with Weill Cornell Drugs on a multi-year analysis collaboration with unique rights to convey UroMap to sufferers. UroMap – developed by Dr. Manikkam Suthanthiran, a pioneer in molecular diagnostics and Chief of Nephrology, Hypertension and Transplantation Drugs at Weill Cornell Drugs and NewYork-Presbyterian/Weill Cornell Medical Heart, and his collaborators at Weill Cornell Drugs – is an extensively studied know-how together with a research revealed within the New England Journal of Medicine. The NEJM research concluded that the UroMap know-how is ready to distinguish acute rejection episodes with excessive accuracy, and should predict future improvement of an acute rejection episode.
Including UroMap to CareDx’s suite of kidney transplant options, which incorporates AlloSure® and KidneyCare™, might probably present healthcare professionals a complete view of immune and harm standing of the transplanted kidney. CareDx’s options allow cutting-edge affected person administration and help optimizing immunosuppression.
“UroMap offers early detection and quantification of clinically related mobile rejection,” mentioned Dr. Suthanthiran, who can also be the named inventor on the patent for the urine gene expression know-how. “We’re hopeful that this take a look at will profit kidney transplant sufferers.”
“We’re delighted to announce this collaboration with Weill Cornell Drugs to assist convey UroMap’s fast allograft rejection detection capabilities to our industry-leading suite of transplant care options,” mentioned Peter Maag, CEO of CareDx. “We proceed our dedication to fund analysis and drive innovation for transplant affected person care.”
CareDx has obtained the unique rights to the UroMap know-how via an unique license settlement with Cornell College, which was negotiated with Cornell College’s know-how switch workplace, Heart for Know-how Licensing at Cornell College (CTL).
About CareDx
CareDx, Inc., headquartered in South San Francisco, California, is a number one precision medication options firm centered on the invention, improvement and commercialization of clinically differentiated, high-value healthcare options for transplant sufferers and caregivers. CareDx gives testing providers, merchandise, and digital healthcare options alongside the pre- and post-transplant affected person journey, and is the main supplier of genomics-based data for transplant sufferers. For extra data, please go to: www.CareDx.com.
CONTACTS:
CareDx, Inc.
Sasha King
Chief Advertising and marketing Officer
415-287-2393
sking@caredx.com
Investor Relations
Greg Chodaczek
646-924-1769
investor@caredx.com
— to www.biospace.com
